Compare SPCE & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCE | CDXS |
|---|---|---|
| Founded | 2017 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Major Chemicals |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.2M | 256.3M |
| IPO Year | 2017 | 2008 |
| Metric | SPCE | CDXS |
|---|---|---|
| Price | $2.88 | $2.33 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $3.06 | N/A |
| AVG Volume (30 Days) | ★ 63.6M | 825.4K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.84 | 43.82 |
| EPS | N/A | ★ N/A |
| Revenue | $1,544,000.00 | ★ $138,590,000.00 |
| Revenue This Year | $2,270.73 | $7.73 |
| Revenue Next Year | $880.03 | $14.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $2.13 | $0.96 |
| 52 Week High | $8.90 | $3.87 |
| Indicator | SPCE | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 44.05 | 44.22 |
| Support Level | $2.63 | $1.57 |
| Resistance Level | $3.01 | $2.69 |
| Average True Range (ATR) | 0.56 | 0.16 |
| MACD | -0.24 | -0.03 |
| Stochastic Oscillator | 11.49 | 26.60 |
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.